证券代码：300379 证券简称：*ST 东通 公告编号：2025-076 北京东方通科技股份有限公司 关于实际控制人、董事长收到中国证券监督管理委员会 立案告知书暨风险提示的公告 （证监立案字 0142025031 号），因涉 嫌信息披露违法违规，根据《中华人民共和国证券法》《中华人民共和国行政处 罚法》等法律法规，中国证监会决定对其立案。 目前，公司生产经营情况一切正常，上述事项不会影响公司正常的生产经营 活动。立案调查期间，黄永军先生将积极配合中国证监会的相关调查工作，公司 将严格按照监管要求履行信息披露义务。 另外，公司于 2025 年 4 月 14 日披露了《关于公司收到中国证券监督管理委 员会立案告知书暨风险提示的公告》 （公告编号：2025-031）。因公司涉嫌定期报 告等财务数据存在虚假记载，被中国证监会立案。若后续经中国证监会行政处罚 认定的事实，触及《深圳证券交易所创业板股票上市规则（2025 年修订）》规定 的重大违法强制退市情形，公司股票将被实施重大违法强制退市。截至本公告披 露日，中国证监会的调查尚在进行中，公司尚未收到就上述立案事项的结论性意 见或决定。 北京东方通科技股份有限公司 ...

北京商报讯（记者 马换换 实习记者 李佳雪）8月6日晚间，*ST东通（300379）披露公告称，公司收到 实际控制人、董事长黄永军通知，其于当日收到证监会送达的《立案告知书》。因涉嫌信息披露违法违 规，证监会决定对其立案。 公告显示，*ST东通于2025年4月14日披露了《关于公司收到中国证券监督管理委员会立案告知书暨风 险提示的公告》。因公司涉嫌定期报告等财务数据存在虚假记载，被证监会立案。若后续经证监会行政 处罚认定的事实，触及重大违法强制退市情形，公司股票将被实施重大违法强制退市。截至公告披露 日，证监会的调查尚在进行中，公司尚未收到就上述立案事项的结论性意见或决定。 *ST东通表示，目前，公司生产经营情况一切正常，上述事项不会影响公司正常的生产经营活动。立案 调查期间，黄永军将积极配合证监会的相关调查工作，公司将严格按照监管要求履行信息披露义务。 交易行情显示，截至8月6日收盘，*ST东通股价报5.68元/股，总市值约31.69亿元。 ...

Group 1 - A total of 59 companies, executives, or shareholders have been investigated by the China Securities Regulatory Commission (CSRC) for violations of information disclosure as of August 5 this year [1] - Companies such as Dahua Intelligent, Knight Dairy, and Jiaotong University Anli have announced investigations since July, with Dahua Intelligent's stock dropping by 20% over three trading days following the announcement [1] - Violations of information disclosure include various situations such as illegal guarantees, fund occupation, changes in actual controllers, and share freezes, which are significant matters that listed companies must disclose [1] Group 2 - Tianmao Group was investigated by the CSRC for failing to disclose its 2024 annual report and 2025 Q1 report within the legal timeframe, leading to a delisting risk warning from the Shenzhen Stock Exchange [2] - Companies under investigation face risks of investor claims after administrative penalties, with most likely to receive orders for correction and fines, while some may face delisting risks due to financial fraud [2] - Stock prices of companies under investigation typically experience a short-term decline following the announcement of the investigation [2]

Core Viewpoint - Guangdong Jiaying Pharmaceutical Co., Ltd. is facing administrative penalties from the China Securities Regulatory Commission (CSRC) for failing to timely disclose related party transactions involving 220 million yuan [1][3][4] Group 1: Company Actions and Violations - Jiaying Pharmaceutical's chairman, Li Neng, is the actual controller of Hunan Yaojuneng Pharmaceutical Co., Ltd., which constitutes a related party [3] - From October 2024 to January 2025, Jiaying Pharmaceutical's subsidiary provided short-term loans to the related party, totaling 219.99 million yuan, which accounted for 28.83% of Jiaying Pharmaceutical's latest audited net assets [3][4] - The company did not follow the required procedures for related party transactions and failed to disclose these transactions in a timely manner [3][4] Group 2: Regulatory Response - The CSRC Guangdong Regulatory Bureau has determined that Jiaying Pharmaceutical's actions violate multiple provisions of the Securities Law, including failure to disclose related party transactions [4] - Proposed penalties include a warning and a fine of 1.5 million yuan for Jiaying Pharmaceutical, 1.6 million yuan for Li Neng, 1 million yuan for Yu Yongping, and 800,000 yuan for Shi Junping [5]

Core Viewpoint - The chairman of Jiaying Pharmaceutical, Li Neng, is facing penalties for misappropriating company funds shortly after taking office, highlighting governance issues within the company [1][2][3]. Group 1: Regulatory Actions - Jiaying Pharmaceutical received an administrative penalty notice from the Guangdong Securities Regulatory Bureau, with potential fines amounting to 1.5 million yuan for the company and additional fines for Li Neng and other responsible parties [1][3]. - The investigation revealed that from October 2024 to January 2025, Jiaying Pharmaceutical's subsidiary provided short-term loans to a company controlled by Li Neng, totaling 220 million yuan, which constituted 28.83% of the company's audited net assets at that time [1][3]. Group 2: Company Background - Jiaying Pharmaceutical, established in 2003 and listed in December 2007, specializes in the research, production, and sales of traditional Chinese medicine, with a focus on proprietary and patented products [8]. - The company has experienced frequent changes in its major shareholders over the years, with the most recent change occurring in 2023 when Dongfang Securities became the largest shareholder [8]. Group 3: Financial Performance - The company's financial performance has been lackluster, with net profits showing minimal growth over the past five years, including a net profit of only 15.4 million yuan in the first quarter of 2025, despite a nearly twofold increase compared to the previous year [1][8]. - From 2020 to 2024, Jiaying Pharmaceutical's net profits were 19.84 million yuan, 1.48 million yuan, 43.93 million yuan, 34.32 million yuan, and 20.61 million yuan, indicating overall stagnant performance [8][9].

Core Viewpoint - Jia Ying Pharmaceutical is facing administrative penalties from the China Securities Regulatory Commission for violations related to information disclosure and improper related-party transactions [3][4] Group 1: Regulatory Actions - The company and its key personnel, including Chairman Li Neng, General Manager You Yongping, and former CFO Shi Junping, received a notice of administrative penalties for failing to disclose related-party transactions properly [3][4] - The Guangdong Regulatory Bureau plans to impose a fine of 1.5 million yuan on Jia Ying Pharmaceutical and varying fines on the individuals involved, with Li Neng facing a fine of 160,000 yuan [4] Group 2: Related-Party Transactions - Between October 2024 and January 2025, Jia Ying Pharmaceutical's subsidiary provided short-term loans to its related party, Hunan Yao Juneng, totaling 220 million yuan, which accounted for 28.83% of the company's audited net assets at that time [3] - The transactions were not conducted in accordance with the required approval procedures and were not disclosed in a timely manner [3] Group 3: Company Background - Jia Ying Pharmaceutical, established in 2003 and listed on the Shenzhen Stock Exchange in 2007, specializes in the research, production, and sales of traditional Chinese medicine [6] - The company has total assets exceeding 1 billion yuan and a market capitalization of nearly 3 billion yuan [6] Group 4: Financial Performance - In 2024, Jia Ying Pharmaceutical reported revenue of 376 million yuan, a year-on-year decrease of 29.46%, and a net profit of 20.61 million yuan, down 39.94% [7] - In the first quarter of 2025, the company saw a revenue increase of 28.83% year-on-year, reaching 122 million yuan, and a net profit increase of 197.23%, totaling 15.40 million yuan [7]

Core Viewpoint - Guangdong Jiaying Pharmaceutical Co., Ltd. is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, leading to potential administrative penalties [1][2]. Group 1: Investigation and Allegations - The company received a notice of investigation from the CSRC on May 28, 2025, due to suspected violations of information disclosure laws [1]. - The investigation revealed that the company's chairman, Li Neng, is the actual controller of Hunan Yaojuneng Pharmaceutical Co., Ltd., which constitutes a related party to Jiaying Pharmaceutical [2]. - Between October 2024 and January 2025, Jiaying Pharmaceutical's subsidiary provided short-term loans to the related party without following the required disclosure procedures, totaling 21.999 million yuan, which accounted for 28.83% of the company's latest audited net assets [2]. Group 2: Administrative Penalties - The CSRC plans to impose administrative penalties, including a warning and a fine of 1.5 million yuan on Jiaying Pharmaceutical, 1.6 million yuan on Li Neng, 1 million yuan on You Yongping, and 800,000 yuan on Shi Junping [3][4]. - The violations were characterized by a short duration and the company’s timely recovery of non-operating funds, which were disclosed in the 2024 annual report [3]. Group 3: Company Response and Impact - The company believes that the penalties will not lead to significant operational impacts and that it does not fall under the major violations that could trigger mandatory delisting [5]. - Jiaying Pharmaceutical has expressed sincere apologies to investors and committed to enhancing compliance awareness and operational standards [5].

Core Viewpoint - The regulatory authority has imposed penalties on Jiaying Pharmaceutical and its responsible individuals for violations related to information disclosure, specifically concerning the failure to timely disclose a 220 million yuan related party fund borrowing [1][2]. Summary by Sections Regulatory Actions - Jiaying Pharmaceutical and its key personnel received a total fine of 4.9 million yuan due to the failure to disclose 220 million yuan in related party fund borrowing [1][2]. - The Guangdong Securities Regulatory Bureau issued a warning and fines of 1.5 million yuan to Jiaying Pharmaceutical, 1.6 million yuan to Chairman Li Neng, 1 million yuan to General Manager You Yongping, and 800,000 yuan to former CFO Shi Junping [3]. Related Party Transactions - The related party transactions involved Jiaying Pharmaceutical's subsidiary, Jiaying Pharmaceutical (Hunan) Co., Ltd., providing short-term fund borrowing to Hunan Yaoyang, a company controlled by Li Neng, with amounts ranging from 40,000 to 59.99 million yuan [2][3]. - The total amount borrowed in 2024 was 170 million yuan, with an additional 50 million yuan in January 2025, representing 28.83% of Jiaying Pharmaceutical's latest audited net assets [2]. Management Accountability - Li Neng, as the chairman, is directly responsible for the information disclosure violations, while You Yongping and Shi Junping also hold direct responsibility due to their managerial roles [3]. - The violations occurred shortly after Li Neng's appointment as chairman, indicating potential misconduct in managing company funds [4]. Financial Context of Related Companies - Hunan Yaoyang, controlled by Li Neng, has faced significant financial challenges, with 2024 revenues of 1.165 billion yuan and a net profit of 49.93 million yuan, which are substantially lower compared to competitors [5]. - The company has struggled to secure financing through public offerings, leading to reliance on brand cooperation and franchise models, resulting in only about 4,000 stores compared to competitors with over 10,000 [5].

Core Viewpoint - Jia Ying Pharmaceutical has been fined a total of 4.9 million yuan due to violations of information disclosure laws, which has raised concerns about its governance and financial practices [3][5][6]. Group 1: Regulatory Actions - Jia Ying Pharmaceutical and related responsible persons received a total fine of 4.9 million yuan from the China Securities Regulatory Commission (CSRC) [3]. - The company’s subsidiary, Hunan Jia Ying, provided a total of 220 million yuan in short-term loans to a company controlled by its actual controller, Li Neng, without proper disclosure [3][6]. - The fines include 150,000 yuan for the company, 1.6 million yuan for Li Neng, 1 million yuan for the general manager, and 800,000 yuan for the former financial director [3]. Group 2: Financial Performance - Jia Ying Pharmaceutical has experienced a decline in revenue and net profit over the past two years, with 2024 revenue dropping to 376 million yuan, a decrease of 29.46% year-on-year, and net profit falling to 20.61 million yuan, down 39.94% [14]. - The company reported a significant drop in operating cash flow, turning negative at -11.83 million yuan, a year-on-year decline of 193.73% [16]. - Accounts receivable surged by 40.48% to 132 million yuan, indicating potential liquidity issues [17]. Group 3: Management Changes - The company has seen frequent changes in its executive team, with the resignation of key personnel including the secretary and financial director earlier this year [12]. - Li Neng took over as chairman of Jia Ying Pharmaceutical in August 2024, shortly before the financial misconduct occurred [7][8]. Group 4: Market Reaction - Following the announcement of the regulatory penalties, Jia Ying Pharmaceutical's stock rose by 3.12%, with a total market capitalization of 3.527 billion yuan as of August 1 [1]. - Since June 20, the stock has experienced an upward trend, with a cumulative increase of over 16% [1].

Core Viewpoint - Guangdong Jiaying Pharmaceutical Co., Ltd. is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, leading to potential administrative penalties [1][2]. Summary by Sections Investigation and Allegations - The CSRC issued a notice of investigation due to Jiaying Pharmaceutical's alleged violations of information disclosure laws, specifically related to transactions with its related party, Hunan Yaojuneng Pharmaceutical Co., Ltd. [1][2]. - Between October 2024 and January 2025, Jiaying Pharmaceutical's subsidiary provided short-term loans to Hunan Yaojuneng, totaling CNY 219.99 million, which accounted for 28.83% of Jiaying Pharmaceutical's latest audited net assets [2]. Legal Basis and Responsibilities - The actions of Jiaying Pharmaceutical are suspected to violate multiple articles of the Securities Law, including provisions regarding the disclosure of related party transactions [3]. - Key executives, including the chairman and general manager, are identified as directly responsible for the violations, with specific penalties proposed for each individual involved [3][4]. Proposed Penalties - The CSRC plans to impose a warning and a fine of CNY 1.5 million on Jiaying Pharmaceutical, along with individual fines for the chairman (CNY 1.6 million), the general manager (CNY 1 million), and the former financial director (CNY 800,000) [4]. Impact on Operations - Despite the ongoing investigation, Jiaying Pharmaceutical's operations remain normal, and the company asserts that the situation will not significantly impact its business activities [4].